-
Australian Journal of General Practice Mar 2023
Topics: Male; Humans; Prostate-Specific Antigen; Decision Making, Shared
PubMed: 36872085
DOI: 10.31128/AJGP-01-23-6692 -
International Journal of Molecular... May 2021Aberrant glycosylation has long been known to be associated with cancer, since it is involved in key mechanisms such as tumour onset, development and progression. This... (Review)
Review
Aberrant glycosylation has long been known to be associated with cancer, since it is involved in key mechanisms such as tumour onset, development and progression. This review will focus on protein glycosylation studies in cells, tissue, urine and serum in the context of prostate cancer. A dedicated section will cover the glycoforms of prostate specific antigen, the molecule that, despite some important limitations, is routinely tested for helping prostate cancer diagnosis. Our aim is to provide readers with an overview of mass spectrometry-based glycoproteomics of prostate cancer. From this perspective, the first part of this review will illustrate the main strategies for glycopeptide enrichment and mass spectrometric analysis. The molecular information obtained by glycoproteomic analysis performed by mass spectrometry has led to new insights into the mechanism linking aberrant glycosylation to cancer cell proliferation, migration and immunoescape.
Topics: Biomarkers, Tumor; Glycosylation; Humans; Male; Mass Spectrometry; Prostate-Specific Antigen; Prostatic Neoplasms; Proteomics
PubMed: 34069262
DOI: 10.3390/ijms22105222 -
Archives of Pathology & Laboratory... Sep 2019
Topics: Factor V; Hepatitis A; Humans; Male; Prostate-Specific Antigen; Thrombophilia
PubMed: 31453732
DOI: 10.5858/arpa.2019-0222-LE -
Revista Da Associacao Medica Brasileira... 2023
Topics: Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Biomarkers, Tumor
PubMed: 36820778
DOI: 10.1590/1806-9282.20221590 -
Investigative and Clinical Urology Sep 2023
Topics: Male; Humans; Prostate-Specific Antigen; Early Detection of Cancer; Prostatic Neoplasms
PubMed: 37668197
DOI: 10.4111/icu.20230229 -
BMC Geriatrics Sep 2023Numerous studies have shown that the dietary inflammatory index (DII) is associated with adverse health effects. However, the relationship between DII and prostate...
BACKGROUND
Numerous studies have shown that the dietary inflammatory index (DII) is associated with adverse health effects. However, the relationship between DII and prostate cancer (PCa) remains controversial. Although alcohol is included in DII as a dietary factor, the various adverse health effects of alcohol consumption are not only related to inflammation. On the other hand, it has been a long-standing debate whether alcohol consumption is linked to the risk of PCa. Therefore, to clarify whether drinking affects the relationship between DII and PCa, we evaluated the correlation between DII and prostate-specific antigen (PSA) based on the National Health and Nutrition Examination Survey (NHANES) database.
METHODS
We used data from the NHANES spanning from 2005 to 2010 to analyze the relationship between PCa and DII. Out of the 31,034 NHANES participants, we enrolled 4,120 individuals in our study, utilizing dietary intake data from a twenty-four-hour period to determine DII scores. Demographic data, physical and laboratory test results were collected to compare between low PSA and high PSA groups, and to calculate the odds ratio between both groups, we employed a logistic regression analysis.
RESULTS
In this cross-sectional investigation of PCa, drinkers and non-drinkers had different relationships between DII and PSA levels (OR: 1.2, 95% Cl: 1-1.44 vs. OR: 0.98, 95% Cl: 0.9-1.07), and DII and abstaining from alcohol were effective in reducing the incidence of PSA (p-value for significant interaction = 0.037).
CONCLUSION
The results of our study suggest that drinking may influence the relationship between DII and PSA levels. DII is likely to be a reliable indicator for estimating PSA levels among non-drinkers, who may limit their intake of pro-inflammatory ingredients to lower the incidence and death of PCa.
Topics: Male; Humans; Prostate-Specific Antigen; Cross-Sectional Studies; Nutrition Surveys; Diet; Ethanol; Drug-Related Side Effects and Adverse Reactions
PubMed: 37670257
DOI: 10.1186/s12877-023-04151-2 -
Tidsskrift For Den Norske Laegeforening... Sep 2023
Topics: Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 37668127
DOI: 10.4045/tidsskr.23.0530 -
American Journal of Men's Health 2020Prostate cancer remains the most common and second most deadly cancer diagnosed amongst U.S. men. External beam radiotherapy is a standard-of-care definitive treatment... (Review)
Review
Prostate cancer remains the most common and second most deadly cancer diagnosed amongst U.S. men. External beam radiotherapy is a standard-of-care definitive treatment option for localized prostate cancer and historically constituted an 8-9-week treatment course comprised of 39-45 doses of 1.8-2.0 Gy each (conventional fractionation, CF). Based on the notion that prostate cancer may respond favorably to a higher dose per day, considerable research efforts have been focused on characterizing the safety and efficacy profile of shorter and shorter radiation courses. Ultrahypofractionation (UHF) involves condensing the radiation course into just 5-7 treatments of 6-8 Gy each. When utilizing modern techniques that allow the precise sculpting of a dose distribution that delivers high doses to the prostate and lower doses to surrounding normal tissues over five or fewer treatments, this treatment is called stereotactic body radiotherapy (SBRT). Two randomized trials (HYPO-RT-PC and PACE-B) have compared UHF to longer radiation courses. The former demonstrated that UHF and CF have similar long-term toxicity and efficacy, while the latter demonstrated that modern SBRT has equivalent short-term toxicity as well. A separate report from a consortium of studies data provides prospective, albeit nonrandomized, data supporting the longer-term safety and efficacy of SBRT specifically. Thus, mounting high-level evidence suggests that SBRT is an acceptable standard care of option for men with localized prostate cancer.
Topics: Humans; Male; Patient Reported Outcome Measures; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dose Hypofractionation
PubMed: 32500805
DOI: 10.1177/1557988320927241 -
Journal of Nuclear Medicine Technology Mar 2023Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents... (Review)
Review
Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (Ga-PSMA-11, F-DCFPyL) and radiopharmaceutical therapy (Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR, and those conducted at the University of California (Los Angeles and San Francisco), as well as the randomized phase 3 therapy trial VISION, have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharmaceutical therapy clinical trials with the β-emitter Lu-PSMA-617 and the α-emitter Ac-PSMA-617 in prostate cancer.
Topics: Male; Humans; Radiopharmaceuticals; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Dipeptides
PubMed: 36599704
DOI: 10.2967/jnmt.122.264928 -
Sensors (Basel, Switzerland) Jul 2021Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized... (Review)
Review
Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay (ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the required sample volume, in the complexity of the analytical procedures, and in adding to the cost. Using companion diagnostic devices such as biosensors, which can be portable and cost-effective with multiplexing capacities, may address these limitations. This review explores recent research for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor platforms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in this review. In addition, this review discusses the importance of converting research protocols into multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a more personalized approach to PCa patients' diagnostic, surveillance and treatment management.
Topics: Biomarkers, Tumor; Biosensing Techniques; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 34372259
DOI: 10.3390/s21155023